--- title: "Capricor Therapeutics (CAPR) news: class action" url: "https://aibio.space/companies/capricor-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "CAPR class action news: Capricor discloses new securities class action and derivative suit as FDA date slips. Capricor Therapeutics, Inc." --- CAPR Capricor Therapeutics, Inc. NASDAQ · United States # Capricor Therapeutics (CAPR) news CAPR class action news Legal · 2026-08-14 ## [Capricor discloses new securities class action and derivative suit as FDA date slips](https://aibio.space/news/capricor-discloses-new-securities-class-action-derivative-suit-fda/) Defendants: Capricor and unnamed officers in the new July 30 class action, and Capricor and CEO Linda Marbán in the 2025 one. The FDA also moved the deramiocel date to November 22, 2026. ## Latest Capricor Therapeutics news 1. 2026-05-07 Legal [Capricor sues Nippon Shinyaku and NS Pharma over Deramiocel U.S. distribution agreement](https://aibio.space/news/capricor-sues-nippon-shinyaku-ns-pharma-deramiocel-u-s-distribution/) Capricor Therapeutics filed a complaint in New Jersey seeking to rescind its January 24, 2022 distribution agreement and asking for a preliminary injunction. The FDA target action date for Deramiocel is August 22, 2026. ## Capricor Therapeutics at a glance - **Ticker**: CAPR - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $237.9 million ### Related companies - [Ernexa Therapeutics](https://aibio.space/companies/ernexa-therapeutics/) NASDAQ: ERNA - [Aoxing Pharmaceutical Company](https://aibio.space/companies/aoxing-pharmaceutical/) OTC: AOXG - [Indaptus Therapeutics](https://aibio.space/companies/indaptus-therapeutics/) NASDAQ: INDP - [Annovis Bio](https://aibio.space/companies/annovis-bio/) NYSE: ANVS - [Damora Therapeutics](https://aibio.space/companies/damora-therapeutics/) NASDAQ: DMRA - [Clene](https://aibio.space/companies/clene/) NASDAQ: CLNN - [Lantern Pharma](https://aibio.space/companies/lantern-pharma/) NASDAQ: LTRN - [Harmony Biosciences Holdings](https://aibio.space/companies/harmony-biosciences/) NASDAQ: HRMY ### Also on NASDAQ - [Kardigan](https://aibio.space/companies/kardigan/) KARD - [CASTLE BIOSCIENCES INC](https://aibio.space/companies/castle-biosciences/) CSTL - [Organogenesis Holdings](https://aibio.space/companies/organogenesis/) ORGO - [biote](https://aibio.space/companies/biote/) BTMD - [Fortrea Holdings](https://aibio.space/companies/fortrea/) FTRE - [AC Immune SA](https://aibio.space/companies/ac-immune/) ACIU ## What Capricor Therapeutics does Capricor Therapeutics, Inc. is a biotechnology company focused on developing and potentially commercializing cell and exosome-based therapeutics for Duchenne muscular dystrophy (DMD) and other diseases with significant unmet medical need. Its lead product candidate, Deramiocel, is a cell therapy made of cardiosphere-derived cells (CDCs), a population of cardiac-derived stromal cells isolated from qualified donated human hearts. The company says Deramiocel is designed to slow disease progression through immunomodulatory, anti-inflammatory, pro-angiogenic and anti-fibrotic activities, which are mediated in part by exosomes secreted by CDCs. Its Biologics License Application for Deramiocel is under review by the FDA, with a PDUFA target action date of August 22, 2026. The company has no products approved for commercial sale. Its clinical development has focused primarily on adolescents and young adults with DMD, many of whom are non-ambulatory. Its exosome platform, StealthX, is being explored for infectious diseases, monogenic diseases and other potential indications, supported by collaborations with the NIH, NIAID, Johns Hopkins University, the Department of Defense, the U.S. Army Institute of Surgical Research and Cedars-Sinai Medical Center. Nippon Shinyaku is the exclusive distributor for DMD in the United States and Japan. | Product or program | What it is | Stage | |---|---|---| | Deramiocel | Cell therapy of cardiosphere-derived cells for Duchenne muscular dystrophy | BLA under FDA review; PDUFA target action date August 22, 2026 | | StealthX exosome platform | Exosome-based therapeutics and vaccines platform under exploration | | Summarised from the company's [10-K filed Mar 17, 2026](https://www.sec.gov/Archives/edgar/data/1133869/000110465926029580/capr-20251231x10k.htm). ## Capricor Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$0](https://www.sec.gov/Archives/edgar/data/1133869/000110465926029580/) | [$22.3 million](https://www.sec.gov/Archives/edgar/data/1133869/000110465926029580/) | | Research and development | [$84.5 million](https://www.sec.gov/Archives/edgar/data/1133869/000110465926029580/) | [$50.0 million](https://www.sec.gov/Archives/edgar/data/1133869/000110465926029580/) | | Net income (loss) | [-$105.0 million](https://www.sec.gov/Archives/edgar/data/1133869/000110465926029580/) | [-$40.5 million](https://www.sec.gov/Archives/edgar/data/1133869/000110465926029580/) | | Cash from operations | [-$69.8 million](https://www.sec.gov/Archives/edgar/data/1133869/000110465926029580/) | [-$40.0 million](https://www.sec.gov/Archives/edgar/data/1133869/000110465926029580/) | | Cash and equivalents | [$287.8 million](https://www.sec.gov/Archives/edgar/data/1133869/000110465926097294/) | [$11.3 million](https://www.sec.gov/Archives/edgar/data/1133869/000110465926029580/) | | Short-term investments | [$30.3 million](https://www.sec.gov/Archives/edgar/data/1133869/000110465926097294/) | [$140.2 million](https://www.sec.gov/Archives/edgar/data/1133869/000110465925109298/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $20.9 million, plus short-term investments of $217.0 million, $237.9 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Capricor Therapeutics Is there a class action against Capricor Therapeutics? Our latest story on this, dated Aug 14, 2026: "Capricor discloses new securities class action and derivative suit as FDA date slips". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/capricor-discloses-new-securities-class-action-derivative-suit-fda/). What is the ticker symbol of Capricor Therapeutics? Capricor Therapeutics, Inc. trades under the ticker CAPR on NASDAQ. Where is Capricor Therapeutics listed? Capricor Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: DUS:4LN2; FWB:4LN2; GETTEX:4LN2; HAM:4LN2; HAN:4LN2; LS:A2PLU4; SWB:4LN2; TRADEGATE:4LN2; XETR:4LN2. What is the SEC CIK of Capricor Therapeutics? The SEC Central Index Key (CIK) for Capricor Therapeutics, Inc. is 1133869. Its filings are on SEC EDGAR. How many shares does Capricor Therapeutics have outstanding? 58,138,989 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-14. Which country or territory is Capricor Therapeutics listed under? Our directory records Capricor Therapeutics, Inc. under United States. What does Capricor Therapeutics do? Our directory classifies Capricor Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Capricor Therapeutics? The ISIN recorded for Capricor Therapeutics, Inc. is US14070B3096. Does aibio.space cover Capricor Therapeutics? aibio.space lists Capricor Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Capricor Therapeutics incorporated? SEC records list its state or country of incorporation as DE. What does Capricor Therapeutics develop? Capricor Therapeutics, Inc. is a biotechnology company focused on developing and potentially commercializing cell and exosome-based therapeutics for Duchenne muscular dystrophy (DMD) and other diseases with significant unmet medical need. Its lead product candidate, Deramiocel, is a cell therapy made of cardiosphere-derived cells (CDCs), a population of cardiac-derived stromal cells isolated from qualified donated human hearts. What is Deramiocel from Capricor Therapeutics? Deramiocel: Cell therapy of cardiosphere-derived cells for Duchenne muscular dystrophy Stage: BLA under FDA review; PDUFA target action date August 22, 2026. What is StealthX exosome platform from Capricor Therapeutics? StealthX exosome platform: Exosome-based therapeutics and vaccines platform under exploration What was Capricor Therapeutics's revenue last year? $0 for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Capricor Therapeutics profitable? Capricor Therapeutics, Inc. reported a net loss of $105.0 million for the fiscal year ended Dec 31, 2025, and used $69.8 million of cash in operations, per its annual report to the SEC. ## Investor discussion: Capricor Therapeutics Members talk about Capricor Therapeutics (CAPR). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Capricor Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-08-14 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1133869/000110465926097294/capr-20260630x10q.htm) 2. 2025-12-04 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1133869/000110465925118481/tm2532720-1_424b5.htm) 3. 2025-09-10 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1133869/000110465925089126/capr-20250910xs3.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:CAPR on TradingView](https://www.tradingview.com/symbols/NASDAQ-CAPR/). ## SEC filings and registration - **SEC name**: Capricor Therapeutics, Inc. - **CIK**: 1133869 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: CAPR (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 10865 ROAD TO THE CURE, SAN DIEGO, CA, 92121 - **Phone**: (310) 358-3200 - **Shares outstanding**: 58,138,989 as of 2026-08-13 (10-Q filed 2026-08-14) - **Former names**: Nile Therapeutics, Inc.; SMI PRODUCTS INC ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1133869/000110465926100071/capr-20260824x8k.htm) filed 2026-08-24 - [10-Q](https://www.sec.gov/Archives/edgar/data/1133869/000110465926097294/capr-20260630x10q.htm) filed 2026-08-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1133869/000110465926095908/capr-20260813x8k.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1133869/000110465926088667/capr-20260729x8k.htm) filed 2026-07-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1133869/000110465926087891/capr-20260729x8k.htm) filed 2026-07-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1133869/000110465926083559/capr-20260709x8k.htm) filed 2026-07-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1133869/000110465926078327/capr-20260626x8k.htm) filed 2026-06-26 - [8-K](https://www.sec.gov/Archives/edgar/data/1133869/000110465926071364/capr-20260604x8k.htm) filed 2026-06-08 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001133869), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Capricor Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker CAPR, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Capricor Therapeutics, Inc. - **Ticker**: CAPR - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US14070B3096 - **Other listed symbols**: DUS:4LN2; FWB:4LN2; GETTEX:4LN2; HAM:4LN2; HAN:4LN2; LS:A2PLU4; SWB:4LN2; TRADEGATE:4LN2; XETR:4LN2 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-CAPR/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/capricor-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Capricor Therapeutics (CAPR) news: class action", 2026-10-31, https://aibio.space/companies/capricor-therapeutics/